26.81 0.00 (0.00%)
After hours: 7:23PM EDT
|Bid||26.10 x 900|
|Ask||26.81 x 800|
|Day's Range||26.35 - 27.86|
|52 Week Range||20.29 - 45.02|
|Beta (3Y Monthly)||3.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.55|
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On October 4, Sangamo Therapeutics (SGMO) stock ended the trading day at $14.81—down ~3.4% from the previous day’s close. The stock registered its 52-week high of $27.50 on February 22. Sangamo Therapeutics reported its 52-week low of $11.30 on October 26, 2017. Currently, the stock is trading ~5.5% lower than its 50-day moving average of $15.68 and ~9% lower than its 200-day moving average of $16.27.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene therapy and oncology, joins the Company as Senior Vice President of Immunogenetics. Dr. Morgan brings to Editas Medicine more than 30 years of scientific leadership in the life sciences industry and at federal research agencies including the National Institutes of Health (NIH).
Here's what has made the best healthcare stocks of this young century the best -- and why some stocks could be poised to join the club.
If you want to know who really controls Editas Medicine Inc (NASDAQ:EDIT), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock inRead More...
Raymond James analyst Steven Seedhouse said the gene-editing pioneer that’s among the year’s hottest biotech stocks appears “crispy and overcooked,” assigning the company its first sell-equivalent rating. While an early-stage study on the drug, in partnership with Vertex Pharmaceuticals Inc., for the treatment of beta thalassemia started recruiting patients in Europe last month, a trial of the treatment in sickle cell disease remains on hold by U.S. regulators. The medicine, CTX001, will be “hard pressed to match” the high levels of hemoglobin increase competitor Bluebird Bio Inc.’s therapy has shown, Seedhouse wrote in a note, warning that Crispr’s early data that are expected next year may disappoint or appear uncompetitive.
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter. In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.
In the second quarter, Editas Medicine (EDIT) reported revenues of $7.3 million from collaborations and other R&D (research and development) activities. In comparison, the company’s revenues reached $3.1 million in the second quarter of 2017.
In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.
Editas Medicine, Inc. (EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, UC) and the Broad Institute, Inc. (Broad) concerning certain CRISPR/Cas9 patents Editas Medicine exclusively licenses from Broad. This favorable action by the CAFC upholds the USPTO decision issued in February 2017, granting Broad’s motion for no interference-in-fact.
The U.S. Court of Appeals for the Federal Circuit affirmed the validity of the Harvard and MIT patents, rejecting a challenge brought by a rival team of researchers associated with the University of California at Berkeley and University of Vienna in Austria. Shares of Cambridge, Massachusetts-based Editas Medicine Inc, a biotechnology company that licenses Harvard and MIT's CRISPR-related patents, rose nearly 7 percent after the ruling before giving back most of those gains and was up 1 percent at $30.56.
In the second quarter, CRISPR Therapeutics reported net income and EPS (earnings per share) of -$38.4 million and -$0.82, respectively, compared to net income and EPS of -$22.3 million and -$0.56 in the second quarter of 2017. In the first half of the year, CRISPR Therapeutics reported net income and EPS of -$66.7 million and -$1.44, respectively, compared to -$43.8 million and -$1.10 in the first half of 2017.
CRISPR Therapeutics (CRSP) has already obtained approval for clinical trial applications (or CTA) across multiple countries for its CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy for the treatment of individuals with severe hemoglobinopathies. CRISPR Therapeutics and its partner, Vertex Pharmaceuticals, obtained CTA approvals for the evaluation of the therapy for the treatment of beta-thalassemia and sickle cell disease.
The three leading CRISPR gene-editing companies announced first-half 2018 earnings last month, and received a boost on the final day of August.
CRISPR gene editing has endured a rough 2018 after years of hype. One start-up, which shares founders and tech with Editas Medicine, thinks it can move the field forward.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D., will be stepping down from the Company at the end of the year. A search is underway to find a successor to Dr. Cox, and the Company continues to execute on its near-term and long-term goals of advancing transformative genomic medicines. “On behalf of the entire Editas team, I sincerely thank Gerry for his many contributions in helping translate the science of CRISPR into medicines,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine.
Over the last six years, a small group of scientists working at different institutes have made incredible progress in a revolutionary new field called gene editing. Gene editing is just what it sounds like. It’s the changing — or “editing” — of an organism’s genes to produce a desired outcome.
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Editas ...
Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.